{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-236658","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.900782+00:00","generated_at":"2026-06-23T17:42:51.084023+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Inhibikase appoints Gisele Dion to Board, replacing retiring Elizabeth O'Farrell","bullets":["Elizabeth O'Farrell retired from the Board effective Sep 1, 2022; departure not due to any disagreement.","Gisele Dion appointed as Class III director effective Sep 1, 2022.","Dion receives $65k annual cash and a 60,000-share option grant (50% vest each of first two anniversaries).","Dion previously SVP & CAO at Takeda, CAO at Shire, and board member at Cytek Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-236658","json":"https://secwatch.observer/filing/0001193125-22-236658.json","markdown":"https://secwatch.observer/filing/0001193125-22-236658.md","text":"https://secwatch.observer/filing/0001193125-22-236658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/d283919d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:42:51.084023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05efca1742","claim":"Gisele Dion was appointed as Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Following Ms. O’Farrell’s resignation, on September 1, 2022, the Board appointed Gisele Dion to serve as a Class III member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"80e60735f2","claim":"Elizabeth O’Farrell retired as Director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"On September 1, 2022, Elizabeth O’Farrell provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of her intention to retire from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}